When Co-founder Hans de Haard heard about Prof. Sally Ward’s immunology research at a conference in San Diego, neither realized just how far it would all lead. Learn more about Prof. Ward’s work in FcRn science and the collaboration that ultimately brought about the development of efgartigimod, a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn).
Follow us
Get the latest news and info via our social media channels.